Business Context and Reporting Period
This Form 8-K filing by Trxade Group, Inc. (a Delaware corporation) reports corporate governance changes effective December 23, 2014. The filing date is December 23, 2014, with the earliest event reported on December 19, 2014. Note: The metadata references "Scienture Holdings, Inc.," but the filing text explicitly identifies the registrant as Trxade Group, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on board composition and director compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from four to five members.
- New Director Election: Donald Almeida, 63, was elected to the Board effective December 23, 2014.
- Independence Status: The addition of Mr. Almeida results in a majority of independent members on the Board.
Outlook, Commentary, and Risks
Management Commentary: The filing highlights Mr. Almeida's extensive background, including 40 years at PricewaterhouseCoopers (PwC) and current board service at WellDoc and Apostherapy. His expertise covers global clients, markets, and industries, particularly in technology and media.
Compensation Arrangements: Mr. Almeida is eligible for non-employee director compensation, including:
- $500 cash fee for each board meeting attended.
- Options to purchase 100,000 shares of Common Stock, vesting over four years at fair market value on the grant date.
Legal Agreements: The company entered into an indemnification agreement with Mr. Almeida (Exhibit 10.1).
Investor Verification Checklist
- Verify the exact number of independent directors currently serving to confirm the "majority independent" status.
- Review the specific vesting schedule and exercise terms of the 100,000 stock options granted to Mr. Almeida.
- Confirm the total outstanding share count to assess the dilution impact of the new option grant.
- Check for any potential conflicts of interest given Mr. Almeida's concurrent board roles at WellDoc and Apostherapy.